You are here: Industry Insights > gilead

News List

Gilead Inks 10-year $5B Deal with Galapagos contractpharma
July 16, 2019
Gains access to Galapagos’ discovery platform and current and future pipeline outside of Europe.
Gilead Appoints CEO of Kite contractpharma
July 15, 2019
Shaw brings extensive experience providing commercial, financial, strategic, medical and operations leadership across the biopharma industry.
Gilead snags Lilly exec Shaw for Kite CEO position fiercepharma
July 13, 2019
Back in May, new Gilead Sciences CEO Daniel O’Day said he’d be looking for a CEO for Gilead’s Kite unit. And he’s found his pick.
Two pharma companies collaborate on long-acting HIV therapy europeanpharmaceuticalreview
July 12, 2019
Two pharmaceutical companies have partnered to develop a slow-release drug to treat patients with HIV.
Gilead partners with Lyndra to create long-acting oral HIV drugs pharmaceutical-technology
July 11, 2019
US-based Lyndra Therapeutics has signed an agreement with Gilead Sciences to develop and commercialise ultra-long acting oral therapies to treat human immunodeficiency virus (HIV).
Nurix and Gilead partner on developing protein degradation drugs pharmaceutical-technology
June 21, 2019
Gilead has signed a global collaboration with Nurix to discover, develop and commercialise a pipeline of protein degradation drugs for cancers and other challenging diseases.
Gilead and Nurix to Collaborate on Novel Therapies contractpharma
June 21, 2019
Consisting of targeted protein degradation drugs for patients with cancer and other challenging diseases.
Gilead, Nurix Announce Collaboration to Develop Novel Therapies for Cancer americanpharmaceuticalreview
June 20, 2019
Gilead Sciences and Nurix Therapeutics announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.
Gilead, AbCellera team up against infectious diseases pharmatimes
June 16, 2019
AbCellera has announced a partnership with Gilead to discover antibodies for infectious disease.
Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says pharmafile
May 15, 2019
Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for HIV drugs, according to a lawsuit filed by AIDS activists and unions.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page